Stock Events

Hikma Pharmaceuticals 

€23.2
215
-€0.4-1.69% Friday 19:39

Statistics

Day High
23.6
Day Low
23.2
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
5.28B
P/E Ratio
30.91
Dividend Yield
3.16%
Dividend
0.73

Upcoming

Dividends

3.16%Dividend Yield
10Y Growth
16.57%
5Y Growth
14.5%
3Y Growth
17.92%
1Y Growth
25.26%

Earnings

8AugExpected
Q4 2023
Q2 2024
0.89
0.98
1.07
1.16
Expected EPS
N/A
Actual EPS
1.1633327

People Also Follow

This list is based on the watchlists of people on Stock Events who follow H5P.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap21.38B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, directly competing with Hikma in the generics and branded drugs markets.
Novartis
NVS
Mkt Cap244.75B
Novartis is a large multinational pharmaceutical company with a strong presence in generic drugs through its Sandoz division, making it a direct competitor to Hikma.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a global pharmaceutical corporation with a broad portfolio that includes generic drugs, competing with Hikma in various therapeutic areas.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie, known for its significant research-based pharmaceuticals, competes with Hikma in the specialty pharmaceuticals market, particularly in areas like immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Hikma in the development and marketing of pharmaceuticals for various therapeutic areas.
Merck
MRK
Mkt Cap300.25B
Merck & Co. is a global healthcare company that competes with Hikma in the development, manufacturing, and marketing of pharmaceuticals and vaccines.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline is a global healthcare company that competes with Hikma in the pharmaceutical and vaccines sectors, with a broad portfolio of products.
Sanofi
SNY
Mkt Cap141.43B
Sanofi is a global pharmaceutical company that competes with Hikma in the areas of generics, specialty care, and vaccines.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Hikma in the development and commercialization of prescription medicines across multiple therapy areas.

About

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Show more...
CEO
Engineer Said Samih Taleb Darwazah
Employees
9100
Country
GB
ISIN
GB00B0LCW083
WKN
000A0HG69

Listings